Cash Flow from Financial Activities: The net amount of cash transactions used in funding activities.
Iovance Biotherapeutics, Inc. (IOVA) had Cash Flow from Financial Activities of $462.96M for the most recently reported fiscal quarter, ending 2023-12-31.
Income Statement Financials | |
$0.48M |
|
$-116.38M |
|
$4.37M |
|
$-3.88M |
|
$121.74M |
|
$-121.26M |
|
$3.12M |
|
$-118.14M |
|
$-118.14M |
|
$-116.38M |
|
$-116.38M |
|
$-116.38M |
|
$-116.38M |
|
$-121.26M |
|
$-113.27M |
|
235.13M |
|
235.13M |
|
$-0.46 |
|
$-0.46 |
|
Balance Sheet Financials | |
$307.85M |
|
$114.03M |
|
$472.50M |
|
$780.35M |
|
$110.31M |
|
$1.00M |
|
$85.43M |
|
$195.74M |
|
$584.61M |
|
$355.36M |
|
$584.61M |
|
256.14M |
|
Cash Flow Statement Financials | |
$-361.82M |
|
$-155.24M |
|
Cash Flow from Financial Activities |
$462.96M |
$238.16M |
|
$181.32M |
|
$-56.84M |
|
$62.62M |
|
-- |
|
-- |
|
Fundamental Metrics & Ratios | |
2.79 |
|
-- |
|
-- |
|
0.00 |
|
0.00 |
|
-805.60% |
|
-25156.84% |
|
-25156.85% |
|
-- |
|
-24509.96% |
|
-24145.02% |
|
$-384.11M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
0.42 |
|
3.19 |
|
28.20 |
|
-19.91% |
|
-32.75% |
|
-14.91% |
|
-19.87% |
|
$2.28 |
|
$-1.63 |
|
$-1.54 |